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Abstract We have cloned the 5P upstream regulatory region of
the mouse somatostatin receptor 2 gene. Its genomic organiza-
tion is novel among all somatostatin receptor genes. It contains
two previously unrecognized exons, separated by introns larger
than 25 kb, and three tissue and cell specific alternative
promoters. The first promoter in front of exon 1 is active only
in AtT-20 tumor cells. The second promoter, located 5P to exon
2, is used in brain, pituitary, adrenals, pancreas, NG 108-15 and
AtT-20 cells. Furthermore, it contains putative DNA elements
for regulation by glucocorticoids, estradiol and cAMP. A third
promoter, located in exon 3, is additionally used in lung, kidney
and spleen.
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1. Introduction
Somatostatin 14 and its N-terminally extended form soma-
tostatin 28 are widely distributed throughout the central nerv-
ous system and peripheral tissues. They act as neurotransmit-
ters or neuromodulators, and in particular as inhibitors of
neurotransmitter release and endocrine and exocrine secretion
(for a review see [1]). The multiple physiological e¡ects of
somatostatin are known to be mediated via ¢ve distinct types
of G protein coupled somatostatin receptors (sst1^sst5) [2^10].
A further degree of genetic diversi¢cation of ssts has been
reported for the subtype 2, which is alternatively spliced to
generate the two isoforms sst2A and sst2B with di¡erent C-
termini [11,12]. Sst2 is involved in inhibition of growth hor-
mone release from the pituitary [13], pancreatic glucagon se-
cretion [14] and gastric acid secretion from stomach [15]. At
the cellular level, sst2 mediates somatostatin evoked inhibition
of cAMP accumulation by coupling to adenylyl cyclase via Gi
proteins [10,16]. As shown more recently, sst2 also couples to
a tyrosine phosphatase, which has been proposed to be in-
volved in inhibition of tumor cell growth observed after clin-
ical administration of somatostatin analogs such as octreotide
[17,18]. Little is known about the genomic structure of sst2
and sst genes in general and the molecular mechanisms con-
trolling transcription in the various tissues. In fact, only ge-
nomic sequences immediately adjacent to the coding regions
of sst genes have been the subject of investigation to date [19^
23]. Here, we report the cloning of the 5P upstream regulatory
region (5P URR) of the mouse sst2 gene. We provide evidence
for the existence of two previously unrecognized exons and
introns and three individual, alternative promoters located
within 50 kb upstream of the protein coding region. In RT-
PCR experiments the usage of the three promoters was exam-
ined in various tissues and cell types.
2. Materials and methods
2.1. Cloning and mapping of genomic fragments of sst2
The exonic sequences of sst2 are contained on two independent
bacteriophage P1 clones of a mouse embryonic stem cell library (Ge-
nome Systems, St. Louis, MO, USA). From P1 clone #24 exon 1 was
obtained, while P1 clone #88 contained exons 2^4. For subcloning
and mapping P1 DNA was ¢rst characterized by restriction enzyme
analysis and Southern blot analysis. Then, appropriate fragments
were subcloned in pBluesript SK3 (Stratagene, Heidelberg, Germany)
according to standard methods [24]. As hybridization probes served
randomly 32P-dATP (Hartmann, Braunschweig) labeled fragments of
a sst2B cDNA [11]. To determine the nucleotide sequence overlapping
inserts of subclones were sequenced on both strands by the dideoxy
chain termination method using the Sequenase II kit (USB, Braun-
schweig, Germany). The size of the ¢rst intron could not be deter-
mined, since exons 1 and 2 are contained on di¡erent, non-overlap-
ping P1 genomic library clones. As revealed by hybridization, exon 1
is located at a distance of at least 15 kb from the 3P end of the P1
clone #24 insert, and exon 2 at least 10 kb from the 5P end of the P1
clone #88 insert. The ¢rst intron thus must be larger than 25 kb. The
size of intron B was determined by hybridization of DNA isolated
from P1 clone #88 with probes for the adjacent exons 2 and 3. A NotI
fragment of about 40 kb contained both exons, whereas various frag-
ments up to 25 kb in size obtained by digestion of P1 DNA with other
restriction enzymes only contained either exon 2 or exon 3. The size of
intron B is thus between 25 and 40 kb.
2.2. Primer extension experiments
Primer extension reactions were preformed with 1 Wg poly(A)
RNA (RNeasy and Oligotex mRNA, Qiagen) and 750 nM oligonu-
cleotide primer (sequences see Fig. 2). The antisense DNA was ex-
tended with 5 units Tth polymerase (Boehringer, Mannheim, Ger-
many) under conditions suggested by the manufacturer with
additionally 10 WCi K-32P-ATP. Cycling conditions were 30 s at
95‡C, 30 s at 60‡C and 1 min at 75‡C for 30 cycles. The products
were analyzed on a 8% denaturing polyacrylamide gel.
2.3. RT-PCR experiments
Total RNA was extracted from various mouse tissues using RNeasy
columns (Qiagen). cDNA was transcribed with random hexamer and
oligo dT primers and Superscript II RT (Gibco BRL). Nucleotide
sequences of primers were as follows: P1 upstream primer: 5P-
GCTGGAGGTAGTCATTGAGCTT-3P, P2 upstream primer: 5P-
CCCGGGCAAGCTCTCTCA-3P, P3 upstream primer: 5P-AGGAA-
GATCTCTAGGCAGCTTG-3P, exon 3 downstream primer: 5P-
TGATGGTCTTCATCTTGGCGT-3P. PCR was performed under
the following conditions: 30 cycles of 1 min at 96‡C, 1 min at 55‡C
and 2 min at 72‡C. To check the integrity of the RNA/cDNA a 605
bp sequence of the glycerine aldehyde phosphate dehydrogenase gene
(GAPDH) was ampli¢ed from the same preparations for 25 cycles of
1 min at 96‡C, 1 min at 60‡C and 3 min at 72‡C. Primers were:
upstream 5P-TGGCAGCTTTCTCCAGGCGGC-3P and downstream
5P-CCCACGGCAAGTTCAACGGCA-3P. PCR products were elec-
trophoresed on 1% agarose gels, blotted and hybridized under strin-
gent conditions (5USSC, 20% formamide; o/n at 63‡C) with a ran-
domly labeled radioactive probe. The washed blots (0.2USSC, 1%
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Fig. 1. (Continued). Nucleotide sequences of the 5P region of the mouse sst2 gene. The sequences of exons are shown in bold, intronic se-
quences are shown in lower case letters. Putative binding sites for several transcription factors are also shown in bold. The dots above indicate
transcription initiation sites. Both 5P splice sites follow the AG/GT rule. The 3P splice site of intron A has the classical NYAG/ but lacks the
pyrimidine-rich stretch in front. The 3P splice site of intron B matches perfectly to the consensus sequence (Y)nNYAG/ (‘/’ is the junction point,
N is A, C, G or T, and Y is C or T).
Fig. 2. Determination of transcription initiation sites. Primer extention experiments using poly(A) RNA isolated from AtT-20 cells revealed
three initiation sites which are depicted schematically along with sequences and primers used (PEX1, PEX2, PEX3). Short arrows indicate the
respective extended fragments in the gel aligned to a co-electrophoresed sequencing reaction for size determination (C and G reaction of pBlue-
script SK3 with an end-labeled M13 reverse primer).
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SDS; 2 times 15 min at 68‡C) were exposed to Kodak X-OMAT
¢lms.
3. Results
3.1. The 5P upstream region of the mouse sst2 gene is divided by
two large introns
We previously reported the cloning of a cDNA encoding
the mouse sst2B isoform, which has a long 5P untranslated
region, containing 590 bp upstream of the ¢rst ATG codon
[11]. Using fragments of this cDNA as probes genomic se-
quences of the upstream region were subcloned from two P1
library clones prepared from mouse 129/SvJ embryonic stem
cells (Genome Systems, St. Louis, MO, USA). The nucleotide
sequences (EMBL Nucleotide Sequence Database, accession
numbers AJ005518, AJ005519, AJ005520) are shown in Fig.
1, Fig. 3A shows the upstream region of the gene schemati-
cally. The 5P URR of the sst2 gene comprises three exons,
separated by two large introns: the ¢rst exon consists of
356 bp (nt 1284^1639). It is separated from exon 2 by at least
25 kb intronic sequences (intron A). Exon 2, which consists of
144 bp (nt 2852^2996) follows intron B, which is 25^40 kb in
size. The sequences encoding the receptor protein start in exon
3 (1083 bp, nt 3557 onwards). The exon-intron junctions are
similar to consensus splice sites [25]. Sequence analysis of the
5P £anking regions of the ¢rst three exons revealed several
motifs similar to binding sites for transcription factors which
typically occur in promoters (see Fig. 1): a classical cAMP
response element (CRE) [26], several putative responsive ele-
ments for glucocorticoids and estrogen (GRE [27], ERE [28],
respectively) and putative binding sites for Yin Yang 1
(YY1)[29]. However, no classical core promoter elements
such as TATA or CAAT boxes are present in the sst2 gene
sequences.
3.2. The sst2 gene has three distinct transcription initiation sites
To determine the transcription initiation site(s) of the
mouse STR2 gene primer extension experiments were per-
formed, which are shown in Fig. 2. The start of exon 1 is
de¢ned by an initiation site located at nt 1284. Additionally,
a second initiation site is located 48 bp 5P to exon 2 (nt 2804)
and a third transcription start site is located at the 26th bp of
exon 3 (nt 3582). These multiple initiation sites suggest the
existence of three individual promoters in the sst2 gene.
3.3. The three sst2 promoters are used cell and tissue
speci¢cally
Next, the transcriptional activity of these promoters was
tested. For the RT-PCR experiments cDNAs were prepared
from various mouse tissues and two cell lines. A fragment of
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Fig. 3. Tissue and cell dependent usage of the sst2 gene promoters.
A: Rationale of the experiments. One common primer located in
exon 3 was used as the 3P downstream primer in combination with
three di¡erent 5P upstream primers. Note that the speci¢c upstream
primer for promoter 2 transcripts is located within the intron, so
that only transcript starting here and not spliced mRNA species
starting in exon 1 are recognized. The upstream primer for the pro-
moter 3 transcripts is located within exon 3. B: RT-PCR with
cDNAs of various tissues and cells. Products of the three primer
pairs speci¢c for the sst2 promoters, P1 (810 bp), P2 (500 bp) and
Pc (279 bp), and GAPDH control (605 bp) are indicated by arrows.
C: Hybridization of the gels with a sst2 probe indicated in A.
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the ubiquitous GAPDH gene cDNA was ampli¢ed as a con-
trol. The results of the experiments are depicted in Fig. 3. Fig.
3A shows the rationale of the experiments schematically with
the location of the di¡erent primers used. The result of a
typical experiment is shown in Fig. 3B. The speci¢city of
the PCR products was demonstrated by hybridization of the
bands with a radioactively labeled probe speci¢c for exon 3
sequences (Fig. 3C). The experiments show that the three
promoters are used in a tissue and cell speci¢c manner: a
PCR product of the ¢rst promoter was only found in
cDNA generated from mouse pituitary AtT-20 cells. Speci¢c
PCR products from the second promoter located in front of
exon 2 were detected in tissues of brain, pituitary, adrenals,
pancreas and stomach, in NG 108-15 neuroblastomaUglioma
hybrid cells and AtT-20 cells. In addition to the cells and
tissues which contain P2 promoter transcripts, cDNA species
starting exclusively from the third promoter were found in
lung, kidney and spleen. No sst2 transcripts were detected in
heart and liver. To demonstrate that these products were not
ampli¢ed merely from incomplete spliced transcripts we per-
formed additional RT-PCR reactions with primers located 5P
of the three determined transcription initiation sites (nt 1226,
2756 and 3508). As expected, use of these upstream primers
together with the common 3P primer did not result in PCR
products (data not shown).
4. Discussion
Our results provide a more complete picture of the structure
of the sst2 gene. The gene covers a range of at least 50 kb on
the genome. The 5P URR comprises two exons and two long
introns. The N-terminal part of the receptor protein including
all of the transmembrane domains is coded by exon 3. A
fourth short exon is critical for the generation of the two
receptor variants sst2A and sst2B as reported earlier [11].
Interestingly, the gene contains three transcription initiation
sites, arranged in such a way that transcripts may start at the
5P border of each of the ¢rst three exons. Consistent with the
assumption that the gene then contains three promoters, a
number of typical promoter elements are present within the
sequences preceding the initiation sites : three putative binding
sites for factor YY1 are present within the sequences in front
of exon 1. This transcription factor is currently recognized as
an important regulator protein whose name re£ects its ambiv-
alent function to serve in many cases as a repressor of the
transcriptional machinery but also as a transcriptional activa-
tor under certain conditions [29]. The presence of such bind-
ing sites may explain why the ¢rst promoter is silent in most
tissues. As shown earlier sst2 mRNA levels are also regulated
by glucocorticoids and estradiol [30,31]. Potential response
elements for such regulation are present on the ¢rst and sec-
ond promoters. The second promoter is active in tissues in
which somatostatin has essential physiological importance
such as brain, pituitary and pancreas. This promoter also
contains a classical CRE. It was observed earlier that sst2
mRNA is upregulated by agents that elevate the intracellular
cAMP level [32], which may be accomplished via this element.
Together, these observations suggest an important physiolog-
ical role of the second promoter. Currently, the activities of all
promoters in transfected cells and the putative transcription
factor interactions are being investigated in our laboratory.
Recently, a promoter was identi¢ed immediately upstream
of the sst2 protein coding region in the human gene. It con-
tains an initiator element that binds a novel transcription
factor and a TC-rich sequence, which was discussed as a pos-
sible transcription factor binding site [23]. The human se-
quences harboring these elements are highly homologous to
the mouse gene. Using RNase protection the authors localized
a transcriptional start site in the human gene which corre-
sponds almost exactly to the intron B/exon 3 junction of the
mouse gene. The TC-rich sequence in the human gene corre-
sponds in the mouse gene to the pyrimidine-rich stretch typ-
ically occurring at 3P splice sites. The high homology to the
murine splice junction includes the possibility that the human
gene may also contain additional upstream exons, which is
currently being tested by us. In the mouse gene transcripts
start 26 bp within exon 3. Transcripts originating exclusively
from this third promoter were found in lung, kidney and
spleen (Fig. 3). Due to the start site of transcription of the
third promoter within the exon the upstream primer P3 will
always also recognize spliced mRNA species derived from
exons 1 and 2. Thus, the question whether the third promoter
is additionally active in those cells and tissues in which one of
the other promoters is used or only in lung, kidney and spleen
cannot be answered by RT-PCR and requires further inves-
tigation, e.g. the use of promoter-transgenic animals. Another
novel feature is the observation of sst2 expression in lung.
Previous studies performed with rat tissue showed only ex-
pression of sst4 in lung [19]. On the other hand, sst2 has
been repeatedly found to be expressed in human lung carci-
noma cells [33,34].
In the last few years the use of multiple promoters has been
shown to be a frequently used mechanism creating diversity
and £exibility in gene expression (for a review see [35]). Alter-
native transcripts of one gene can be generated that either are
di¡erentially regulated in di¡erent tissues [36] or developmen-
tal stages [37], or respond in di¡erent ways to various stimuli
[38]. We have shown for the ¢rst time that a somatostatin
receptor gene belongs to this group of genes featuring a com-
plex 5P untranslated region and tissue dependent alternative
promoter usage. Further investigations will reveal whether the
other sst types have similar genomic structures.
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